Possible prevention of tuberous sclerosis complex lesions

Pediatrics

Volumn 132, Issue 1, 2013, Pages

  Kotulska, Katarzyna ^a,b   Borkowska, Julita ^b   Jozwiak, Sergiusz ^b  

^a Departments of aScience   (Poland)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Everolimus; MTOR; Prevention; Renal AML; SEGA; Skin lesions; Tuberous sclerosis complex

Indexed keywords

EVEROLIMUS; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ANGIOMYOLIPOMA; ARTICLE; AUTISM; CASE REPORT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; ECHOGRAPHY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMANGIOFIBROMA; HUMAN; HYPERLIPIDEMIA; INFANT; INFANTILE SPASM; MONOZYGOTIC TWINS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; SEIZURE; SIDE EFFECT; SKIN EXAMINATION; STOMATITIS; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TREATMENT DURATION; TUBEROUS SCLEROSIS; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

EID: 84879993148     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-3607     Document Type: Article

References (14)

1. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639): 657-668
2. Józwiak S, Schwartz RA, Janniger CK, Bielicka-Cymerman J. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol. 2000; 15(10):652-659
3. Dabora SL, Jozwiak S, Franz DN, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64-80
4. Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc. 1991;66 (8):792-796
5. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis complex: A multicentre, randomized, placebo-controlled trial. Lancet. 2013;381 (9861):125-132
6. Martin N, Zügge K, Brandt R, Friebel D, Janssen B, Zimmerhackl LB. Discordant clinical manifestations in monozygotic twins with the identical mutation in the TSC2 gene. Clin Genet. 2003;63(5): 427-430
7. Humphrey A, Higgins JN, Yates JR, Bolton PF. Monozygotic twins with tuberous sclerosis discordant for the severity of developmental deficits. Neurology. 2004;62(5): 795-798
8. Lyczkowski DA, Conant KD, Pulsifer MB, et al. Intrafamilial phenotypic variability in tuberous sclerosis complex. J Child Neurol. 2007;22(12):1348-1355
9. Au KS, Hebert AA, Roach ES, Northrup H. Complete inactivation of the TSC2 gene leads to formation of hamartomas. Am J Hum Genet. 1999;65(6):1790-1795
10. Anderl S, Freeland M, Kwiatkowski DJ, Goto J. Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex. Hum Mol Genet. 2011;20(23):4597-4604
11. Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008;63(4):444-453
12. Way SW, Rozas NS, Wu HC, et al. The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex. Hum Mol Genet. 2012;21(14):3226-3236
13. González D, García CD, Azócar M, et al. Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr Nephrol. 2011;26(6):961-966
14. Józwiak S, Stein K, Kotulska K. Everolimus (RAD001): First systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Future Oncol. 2012;8(12):1515-1523